Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BTAI
BTAI logo

BTAI News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

BTAI News

BioXcel to Host Virtual Event on April 23 to Discuss Launch Strategy for IGALMI

3d agoNewsfilter

Investigation into BioXcel Therapeutics' Corporate Governance Breaches

Apr 10 2026PRnewswire

BioXcel Initiates Phase 2a Study for Acute Stress Reactions

Apr 08 2026NASDAQ.COM

BioXcel Initiates Clinical Trial for ASR Treatment

Apr 08 2026Newsfilter

BioXcel Submits sNDA for IGALMI® in At-Home Treatment

Mar 27 2026Newsfilter

BioXcel Therapeutics Q4 Earnings Beat Expectations

Mar 27 2026seekingalpha

BioXcel Therapeutics Enters Securities Purchase Agreement for $8 Million Offering

Mar 10 2026Newsfilter

BioXcel Therapeutics Shares Decline Despite Positive Drug Development News

Mar 06 2026Benzinga

BTAI Events

04/08 07:10
BioXcel Therapeutics Begins U.S. War Department-Funded Clinical Trial
BioXcel Therapeutics announced the enrollment of the first patients in a U.S. Department of War-funded Phase 2a clinical trial evaluating BXCL501 for the treatment of acute stress reactions, also known as acute stress disorder. The trial is being led by the University of North Carolina at Chapel Hill Institute of Trauma Recovery and marks a significant milestone in the collaboration between BioXcel Therapeutics and UNC.
04/01 07:10
BioXcel Therapeutics' Igalmi sNDA Accepted by FDA
BioXcel Therapeutics announced that the FDA has accepted its supplemental new drug application, or sNDA, for approval of Igalmi for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia. The FDA has assigned a Prescription Drug User Fee Act target action date of November 14.
03/27 09:00
Stock Futures Modestly Lower as Energy Prices Rise
Stock futures are modestly lower ahead of the open, indicating a weaker start. The move follows another sharp decline in the prior session, where the S&P 500 fell more than 1% and the Nasdaq dropped over 2%, moving into correction territory.The primary driver remains energy. Oil prices are rising again, with Brent crude trading above $110 per barrel. Although prices are on track for a slight weekly decline, they remain significantly elevated due to ongoing supply disruptions tied to the Iran conflict.That persistence in elevated oil prices is continuing to feed into broader market conditions. Treasury yields are climbing, with the 10-year approaching the mid-4% range, and rate expectations have shifted meaningfully. Markets that previously anticipated rate cuts are now pricing in the possibility of further tightening, reflecting concern that the energy shock could keep inflation elevated.In pre-market trading, S&P 500 futures fell 0.45%, Nasdaq futures fell 0.67% and Dow futures fell 0.39%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -AstraZenecaup 4% after announcing tozorakimab met the primary endpoint in OBERON and TITANIA trialsUP AFTER EARNINGS -Newsmaxup 12%Arganup 10%Legenceup 9%BioXcel Therapeuticsup 3%DOWN AFTER EARNINGS -Humacytedown 7%P3 Health Partnersdown 6%Autolus Therapeuticsdown 4%Laird Superfooddown 4%LOWER -Two Harborsdown 1% after entering into a definitive merger agreement pursuant to which CrossCountry will acquire all of the outstanding shares of Two Harbors common stock for $10.80 per share in cash

BTAI Monitor News

BioXcel Therapeutics rises amid sector rotation

Mar 05 2026

BTAI Earnings Analysis

No Data

No Data

People Also Watch